ASH 2013: Adcetris Tested Against B-cell Non-Hodgkin's Lymphomas

Although Adcetris is associated with Hodgkin's and T-cell lymphoma, researchers have been testing the drug for use against non-Hodgkin's lymphomas with some encouraging success.

This ongoing open-label phase II study conducted by researchers at Dana-Farber Cancer Institute and MD Anderson Cancer center, among others, is exploring the activity of the antibody drug conjugate brentuximab vedotin (Adcetris) against relapsed or refractory non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL).

A total of 62 patients have been enrolled in the study, including 44 with DLBCL. The majority of patients are heavily pretreated and have refractory disease.

Surprising results

Among the DLBCL patients, 40 percent had an objective response to Adcetris, with a median duration of 36 weeks. Seven patients had complete remissions and 10 had partial responses.

Researchers expressed encouragement over the activity seen against DLBCL, since their hopes weren't all that high.

Adcetris seeks the CD30 protein on the cell surface, which is how it finds the cells it is designed to kill – a protein expressed by maybe one-third of NHL B-cell patients.

Curiously, investigators found that Adcetris seemed to work as well as or better in those patients whose tumor weakly expressed the CD30 protein – this is contrary to all expectation and to preclinical trials.

No explanation for the activity was offered.

Source: ASH

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...